Company Overview of OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem Cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates under development include Anti-DLL4 (demcizumab, OMP-21M18), a humanized monoclonal antibody that is in Phase Ib combination therapy trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-VEGF Bispecific, which has completed preclinical trail that targets and in...
800 Chesapeake Drive
Redwood City, CA 94063
Founded in 2004
Key Executives for OncoMed Pharmaceuticals, Inc.
Co-Founder and Member of Scientific & Clinical Advisory Board
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Chief Scientific Officer and Executive Vice President
Compensation as of Fiscal Year 2012.
OncoMed Pharmaceuticals, Inc. Key Developments
OncoMed Pharmaceuticals, Inc. Presents Phase 1 Data in Solid Tumor Patients for the First-In-Class Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
Jun 3 13
OncoMed Pharmaceuticals, Inc. highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL. Vantictumab is a first-in-class antibody that has broad anti-cancer stem cell and anti-tumor activity in patient-derived xenograft tumor models. The presentation at ASCO (Abstract 2540), entitled 'First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the Wnt pathway in a Phase I study for patients with advanced solid tumors,' was the first clinical presentation of this novel agent. Dr. David Smith (University of Michigan Cancer Center at Ann Arbor, MI) presented the data on behalf of the other principal investigators (Dr. Lee Rosen at the University of California, Los Angeles, CA, and Dr. Kyriakos Papadopoulos at The START Center for Cancer Care, San Antonio, TX) and the entire study team. In the ongoing trial of 24 patients, vantictumab was generally well tolerated up to the current dose of 10 mg/kg every three weeks. A bone protection strategy has been successful in ensuring bone health. Pharmacodynamic effects of vantictumab on the Wnt pathway in patient samples have been noted. Three patients with neuroendocrine tumors (NET) experienced prolonged stable disease for 110, 316+, and 385+ days. Based on these data, OncoMed has advanced vantictumab into three Phase 1b trials in specific tumor indications to study its safety in combination with standard-of-care chemotherapy. These trials will initiate in 2013. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer HealthCare.
OncoMed Pharmaceuticals, Inc. Presents at Wells Fargo 2013 Healthcare Conference, Jun-19-2013
May 31 13
OncoMed Pharmaceuticals, Inc. Presents at Wells Fargo 2013 Healthcare Conference, Jun-19-2013 . Venue: Intercontinental Hotel, Rose Kennedy Ballroom (3rd Floor), 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: John A. Lewicki, Chief Scientific Officer and Executive Vice President, Paul J. Hastings, Chief Executive Officer, President and Director, Shari Annes, IR, William D. Waddill, Chief Financial Officer, Senior Vice President, Treasurer and Assistant Secretary.
OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-03-2013
May 21 13
OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-03-2013 . Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|